The Ninth Annual Pharmacogenetics in Psychiatry Meeting

第九届精神病学药物遗传学年会

• 批准号: 8055024
• 负责人: Anil K Malhotra
• 金额: --
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-02 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8055024
• 关键词: Academia; Adverse effects; Antidepressive Agents; Antipsychotic Agents; Area; Award; Caring; Clinical; Clinical Trials; Data; Development; Educational Grants; Evaluation; Fees; Financial Support; Funding; Genes; Genetic; Growth; Health; Hospitals; Industry; Mediating; Medicine; Mentally Ill Persons; Molecular; National Institute of Mental Health; New York City; Patients; Pharmacogenetics; Psychiatry; Psychotropic Drugs; Request for Applications; Research; Research Personnel; Resources; Schedule; Source; Travel; Variant; Work; base; career; clinical practice; genome wide association study; interdisciplinary approach; interest; meetings; novel; programs; response

DESCRIPTION (provided by applicant): The annual Pharmacogenetics in Psychiatry (PIP) meeting has provided a unique forum for the presentation and discussion of new developments in the field of psychiatry pharmacogenetics for the past eight years. Previous meetings have been highlighted by discussion of topics including: prediction of clinical response to antipsychotic and antidepressant drugs; genes associated with the development of adverse side effects; novel statistical approaches; and most recently, the implication of genome-wide association (GWAS) approaches for pharmacogenetics. Moreover, the meeting has brought together investigators working in diverse areas of research, from molecular geneticists to clinical trial investigators, from academia and industry in order to engender true interdisciplinary approaches to the problem of variation in clinical response to psychotropic drugs. The meetings have been highly successful as evidenced by continued growth in participation, excellent evaluations from meeting attendees, and the number of collaborative efforts that have grown out of meeting participation. The prior PIP meetings have taken place in New York City with pooled support from a variety of sources: The Zucker Hillside Hospital, industry supported unrestricted educational grants, and registration fees. Because we believe that this program should have stable, independent financial support on an ongoing basis, in this application, we request support from the NIMH to enable us to continue this meeting in the face of declining financial support from other resources. Moreover, we hope to provide Travel Awards to deserving new investigators interested in developing research careers in this rapidly developing field. Therefore, in this application, we seek support for additional five years of funding for the annual PIP meeting, with the next meeting scheduled in New York City, April 23 & 24, 2010. PUBLIC HEALTH RELEVANCE: Psychiatric pharmacogenetics is a rapidly evolving field of research that aims to identify genetic factors mediating the variation in psychotropic drug response. The introduction of pharmacogenetics into clinical practice would have significant impact on the care of mentally ill patients and the PIP meeting serves to provide a dedicated forum for the presentation and discussion of the latest data in this area of "personalized medicine".

描述（由申请人提供）：年度精神病学药物遗传学（PIP）会议为展示和讨论过去八年精神病学药物遗传学领域的新发展提供了一个独特的论坛。之前的会议重点讨论了以下主题：预测抗精神病药物和抗抑郁药物的临床反应；与不良副作用发生相关的基因；新颖的统计方法；最近，全基因组关联（GWAS）方法对药物遗传学的影响。此外，会议汇集了来自学术界和工业界的不同研究领域的研究人员，从分子遗传学家到临床试验研究人员，以便针对精神药物临床反应变异问题提出真正的跨学科方法。这些会议非常成功，参与人数的持续增长、与会者的出色评价以及因会议参与而产生的协作努力的数量都证明了这一点。 之前的 PIP 会议在纽约市举行，得到了各种来源的共同支持：Zucker Hillside 医院、行业支持​​的无限制教育补助金和注册费。因为我们认为该计划应该持续获得稳定、独立的财务支持，所以在本申请中，我们请求 NIMH 的支持，以使我们能够在其他资源的财务支持不断减少的情况下继续举行这次会议。此外，我们希望为有兴趣在这个快速发展的领域发展研究事业的新研究人员提供旅行奖。因此，在此申请中，我们寻求为年度 PIP 会议提供额外五年的资金支持，下一次会议定于 2010 年 4 月 23 日至 24 日在纽约市举行。 公共卫生相关性：精神药物遗传学是一个快速发展的研究领域，旨在识别介导精神药物反应变化的遗传因素。将药物遗传学引入临床实践将对精神疾病患者的护理产生重大影响，PIP会议为展示和讨论“个性化医疗”这一领域的最新数据提供了一个专门的论坛。